Indaptus Therapeutics Inc Total Assets
Indaptus Therapeutics Inc total assets. Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) holds total assets worth $11.99 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Indaptus Therapeutics Inc (INDP) total market value for the company's overall valuation and market capitalisation.
Total Assets of Indaptus Therapeutics Inc (2008–2025)
Total assets of Indaptus Therapeutics Inc from 2008 to 2025. This chart illustrates how Indaptus Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Indaptus Therapeutics Inc (INDP) share price today for real-time trading data and today's change.
Indaptus Therapeutics Inc - Asset Composition Analysis
Indaptus Therapeutics Inc Total Assets Breakdown (December 2025)
Indaptus Therapeutics Inc total assets breakdown as of December 2025. Indaptus Therapeutics Inc's total assets of $11.99 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Indaptus Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Indaptus Therapeutics Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Indaptus Therapeutics Inc's current assets represent 100.0% of total assets in 2025, an increase from 41.0% in 2008.
- Cash Position: Cash and equivalents constituted 91.4% of total assets in 2025, up from 30.9% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Indaptus Therapeutics Inc Competitors by Total Assets
Key competitors of Indaptus Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Indaptus Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.48 | 0.75 | 7.59 |
| Quick Ratio | 19.48 | 0.75 | 7.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $11.37 Million | $-2.10 Million | $38.07 Million |
Indaptus Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Indaptus Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 44.17 |
| Latest Market Cap to Assets Ratio | 33.92 |
| Asset Growth Rate (YoY) | 26.9% |
| Total Assets | $9.31 Million |
| Market Capitalization | $315.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Indaptus Therapeutics Inc's assets at a significant premium (33.92x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Indaptus Therapeutics Inc's assets grew by 26.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Indaptus Therapeutics Inc (2008–2025)
The table below shows the annual total assets of Indaptus Therapeutics Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $9.31 Million | +26.86% |
| 2024-12-31 | $7.34 Million | -50.83% |
| 2023-12-31 | $14.92 Million | -46.82% |
| 2022-12-31 | $28.06 Million | -30.84% |
| 2021-12-31 | $40.58 Million | +2182.41% |
| 2020-12-31 | $1.78 Million | -91.65% |
| 2019-12-31 | $21.28 Million | -65.40% |
| 2018-12-31 | $61.51 Million | -4.71% |
| 2017-12-31 | $64.55 Million | +161.11% |
| 2016-12-31 | $24.72 Million | -33.68% |
| 2015-12-31 | $37.28 Million | +198.35% |
| 2014-12-31 | $12.49 Million | -8.67% |
| 2013-12-31 | $13.68 Million | +76.09% |
| 2012-12-31 | $7.77 Million | -14.25% |
| 2011-12-31 | $9.06 Million | -27.76% |
| 2010-12-31 | $12.54 Million | +280.87% |
| 2009-12-31 | $3.29 Million | +52.51% |
| 2008-12-31 | $2.16 Million | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more